Screener
10x Genomics, Inc. TXG Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by 10x Genomics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The source filing: 10x Genomics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 6, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054491
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchase of equity interest rights | (500) | — |
| Net cash used in investing activities | (9,046) | (2,832) |
| Financing activities: | ||
| Issuance of common stock from exercise of stock options | 3,289 | 3,944 |
| Payment of contingent consideration | (8,690) | — |
| Net cash provided by (used in) financing activities | (5,401) | 3,944 |
| Effect of exchange rates changes on cash and cash equivalents | (101) | 474 |
| Net increase in cash and cash equivalents | 28,546 | 53,645 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is 10x Genomics, Inc.'s stock issuance proceeds?
- 10x Genomics, Inc. (TXG) reported stock issuance proceeds of $3.02M in Q2 2026.
- How has 10x Genomics, Inc.'s stock issuance proceeds changed year-over-year?
- 10x Genomics, Inc.'s stock issuance proceeds decreased by 14.4% year-over-year, from $3.52M to $3.02M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about 10x Genomics, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude